To fight or die-inhibitor of apoptosis proteins at the crossroad of innate immunity and death

Current Opinion in Cell Biology

Volumn 22, Issue 6, 2010, Pages 872-881

  Lopez, Juanita ^a   Meier, Pascal ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR;

CELL SURVIVAL; CELL VIABILITY; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL DEATH; DEAD-BOX RNA HELICASES; EVOLUTION, MOLECULAR; HUMANS; IMMUNITY, INNATE; INHIBITOR OF APOPTOSIS PROTEINS; NF-KAPPA B; NOD SIGNALING ADAPTOR PROTEINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

INTRACISTERNAL A-PARTICLES;

EID: 78649635741     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2010.08.025     Document Type: Review

References (76)

1. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010, 10:561-574.
2. Komander D. The emerging complexity of protein ubiquitination. Biochem Soc Trans 2009, 37:937-953.
3. Kirisako T., Kamei K., Murata S., Kato M., Fukumoto H., Kanie M., Sano S., Tokunaga F., Tanaka K., Iwai K. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 2006, 25:4877-4887.
4. Bhoj V.G., Chen Z.J. Ubiquitylation in innate and adaptive immunity. Nature 2009, 458:430-437.
5. Xu P., Duong D.M., Seyfried N.T., Cheng D., Xie Y., Robert J., Rush J., Hochstrasser M., Finley D., Peng J. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009, 137:133-145.
6. Hoeller D., Hecker C.M., Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006, 6:776-788.
7. Tokunaga F., Sakata S., Saeki Y., Satomi Y., Kirisako T., Kamei K., Nakagawa T., Kato M., Murata S., Yamaoka S., et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol 2009, 11:123-132.
8. Broemer M., Meier P. Ubiquitin-mediated regulation of apoptosis. Trends Cell Biol 2009, 19:130-140.
9. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733.
10. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
11. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
12. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62.
13. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25:280-288.
14. Bianchi K., Meier P. A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. Mol Cell 2009, 36:736-742.
15. Huh J.R., Foe I., Muro I., Chen C.H., Seol J.H., Yoo S.J., Guo M., Park J.M., Hay B.A. The Drosophila inhibitor of apoptosis (IAP) DIAP2 is dispensable for cell survival, required for the innate immune response to Gram-negative bacterial infection, and can be negatively regulated by the reaper/hid/grim family of IAP-binding apoptosis inducers. J Biol Chem 2007, 282:2056-2068.
16. Leulier F., Lhocine N., Lemaitre B., Meier P. The Drosophila inhibitor of apoptosis protein DIAP2 functions in innate immunity and is essential to resist Gram-negative bacterial infection. Mol Cell Biol 2006, 26:7821-7831.
17. Kleino A., Valanne S., Ulvila J., Kallio J., Myllymaki H., Enwald H., Stoven S., Poidevin M., Ueda R., Hultmark D., et al. Inhibitor of apoptosis 2 and TAK1-binding protein are components of the Drosophila Imd pathway. EMBO J 2005, 24:3423-3434.
18. Gesellchen V., Kuttenkeuler D., Steckel M., Pelte N., Boutros M. An RNA interference screen identifies Inhibitor of Apoptosis Protein 2 as a regulator of innate immune signalling in Drosophila. EMBO Rep 2005, 6:979-984.
19. Paquette N., Broemer M., Aggarwal K., Chen L., Husson M., Erturk-Hasdemir D., Reichhart J.M., Meier P., Silverman N. Caspase-mediated cleavage, IAP binding, and ubiquitination: linking three mechanisms crucial for Drosophila NF-kappaB signaling. Mol Cell 2010, 37:172-182.
20. Gaither A., Porter D., Yao Y., Borawski J., Yang G., Donovan J., Sage D., Slisz J., Tran M., Straub C., et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007, 67:11493-11498.
21. Santoro M.M., Samuel T., Mitchell T., Reed J.C., Stainier D.Y. Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet 2007, 39:1397-1402.
22. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
23. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos C.A., Chunduru S.K., Condon S.M., McKinlay M., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
24. Bertrand M.J., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., Gillard J.W., Jaquith J.B., Morris S.J., Barker P.A. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008, 30:689-700.
25. Mahoney D.J., Cheung H.H., Mrad R.L., Plenchette S., Simard C., Enwere E., Arora V., Mak T.W., Lacasse E.C., Waring J., et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A 2008, 105:11778-11783.
26. Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.H., Keats J.J., Wang H., Vignali D.A., Bergsagel P.L., Karin M. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008, 9:1364-1370.
27. Varfolomeev E., Goncharov T., Fedorova A.V., Dynek J.N., Zobel K., Deshayes K., Fairbrother W.J., Vucic D. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008, 283:24295-24299.
28. Vince J.E., Chau D., Callus B., Wong W.W., Hawkins C.J., Schneider P., McKinlay M., Benetatos C.A., Condon S.M., Chunduru S.K., et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008, 182:171-184.
29. Haas T.L., Emmerich C.H., Gerlach B., Schmukle A.C., Cordier S.M., Rieser E., Feltham R., Vince J., Warnken U., Wenger T., et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 2009, 36:831-844.
30. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
31. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703.
32. Petersen S.L., Wang L., Yalcin-Chin A., Li L., Peyton M., Minna J., Harran P., Wang X. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007, 12:445-456.
33. O'Donnell M.A., Legarda-Addison D., Skountzos P., Yeh W.C., Ting A.T. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol 2007, 17:418-424.
34. Geserick P., Hupe M., Moulin M., Wong W.W., Feoktistova M., Kellert B., Gollnick H., Silke J., Leverkus M. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol 2009, 187:1037-1054.
35. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002, 8:808-815.
36. Fandy T.E., Shankar S., Srivastava R.K. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008, 7:60.
37. Lecis D., Drago C., Manzoni L., Seneci P., Scolastico C., Mastrangelo E., Bolognesi M., Anichini A., Kashkar H., Walczak H., et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer 2010, 102:1707-1716.
38. Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., Chan F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137:1112-1123.
39. He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009, 137:1100-1111.
40. Galluzzi L., Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell 2008, 135:1161-1163.
41. Zhang D.W., Shao J., Lin J., Zhang N., Lu B.J., Lin S.C., Dong M.Q., Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336.
42. Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O., Teng X., Abbott D., Cuny G.D., Yuan C., Wagner G., et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008, 4:313-321.
43. Benson M.J., Dillon S.R., Castigli E., Geha R.S., Xu S., Lam K.P., Noelle R.J. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008, 180:3655-3659.
44. Senftleben U., Cao Y., Xiao G., Greten F.R., Krahn G., Bonizzi G., Chen Y., Hu Y., Fong A., Sun S.C., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499.
45. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., Shiba T., Yang X., Yeh W.C., Mak T.W., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008, 9:1371-1378.
46. Grech A.P., Amesbury M., Chan T., Gardam S., Basten A., Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004, 21:629-642.
47. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
48. Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.J., Van Wier S., Tiedemann R., Shi C.X., Sebag M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
49. Yamaguchi N., Ito T., Azuma S., Ito E., Honma R., Yanagisawa Y., Nishikawa A., Kawamura M., Imai J., Watanabe S., et al. Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci 2009, 100:1668-1674.
50. Wharry C.E., Haines K.M., Carroll R.G., May M.J. Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells. Cancer Biol Ther 2009, 8:1567-1576.
51. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275.
52. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
53. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
54. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140:871-882.
55. Bauler L.D., Duckett C.S., O'Riordan M.X. XIAP regulates cytosol-specific innate immunity to Listeria infection. PLoS Pathog 2008, 4:e1000142.
56. Bertrand M.J., Doiron K., Labbe K., Korneluk R.G., Barker P.A., Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 2009, 30(6):789-801.
57. Krieg A., Correa R.G., Garrison J.B., Le Negrate G., Welsh K., Huang Z., Knoefel W.T., Reed J.C. XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci U S A 2009, 106:14524-14529.
58. Chen G., Shaw M.H., Kim Y.G., Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009, 4:365-398.
59. Inohara N., Koseki T., Lin J., del Peso L., Lucas P.C., Chen F.F., Ogura Y., Nunez G. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 2000, 275:27823.
60. Hasegawa M., Fujimoto Y., Lucas P.C., Nakano H., Fukase K., Nunez G., Inohara N. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J 2008, 27:373-383.
61. Yang Y., Yin C., Pandey A., Abbott D., Sassetti C., Kelliher M.A. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem 2007, 282:36223-36229.
62. Park J.H., Kim Y.G., McDonald C., Kanneganti T.D., Hasegawa M., Body-Malapel M., Inohara N., Nunez G. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 2007, 178:2380-2386.
63. Rajalingam K., Sharma M., Paland N., Hurwitz R., Thieck O., Oswald M., Machuy N., Rudel T. IAP-IAP complexes required for apoptosis resistance of C. trachomatis-infected cells. PLoS Pathog 2006, 2:e114.
64. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
65. Tseng P.H., Matsuzawa A., Zhang W., Mino T., Vignali D.A., Karin M. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 2010, 11:70-75.
66. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
67. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
68. Mao A.P., Li S., Zhong B., Li Y., Yan J., Li Q., Teng C., Shu H.B. Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-beta) and cellular antiviral response. J Biol Chem 2010, 285:9470-9476.
69. Meier P., Vousden K.H. Lucifer's labyrinth-ten years of path finding in cell death. Mol Cell 2007, 28:746-754.
70. Hunter A.M., LaCasse E.C., Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007, 12:1543-1568.
71. McManus D.C., Lefebvre C.A., Cherton-Horvat G., St-Jean M., Kandimalla E.R., Agrawal S., Morris S.J., Durkin J.P., Lacasse E.C. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004, 23:8105-8117.
72. Shaw T.J., Lacasse E.C., Durkin J.P., Vanderhyden B.C. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int J Cancer 2008, 122:1430-1434.
73. Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., Luo J.L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
74. Wu Y., Zhou B.P. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010, 102:639-644.
75. Mace P.D., Linke K., Feltham R., Schumacher F.R., Smith C.A., Vaux D.L., Silke J., Day C.L. Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment. J Biol Chem 2008, 283:31633-31640.
76. Mace P.D., Smits C., Vaux D.L., Silke J., Day C.L. Asymmetric recruitment of cIAPs by TRAF2. J Mol Biol 2010, 400:8-15.